cgc-11047
Small moleculeexperimental
Clinical trial activity
5 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2005 (NCT00705653)
Timeline
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Loading structure…
SMILES
CCNCCCNC/C=C\CNCCCNCC- Mol. weight
- 256.44 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL142464 ↗
Also known as
- ((1)n,(12)n)bis(ethyl)-6,7-dehydrospermine
- cgc11047
- cgc 11047
- cgc-11047
- cgc-11047
- cgc-11047
- cgc-11047
- (n(1),n(12))bis(ethyl)-6,7-dehydrospermine
- pg11047
- pg-11047
- pg-11047
- pg-11047
- sl 11047
- sl-11047
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00446654 | Phase 1 | Apr 1, 2007 | Johns Hopkins University, Progen Pharmaceuticals |
| NCT00585416 | Phase 2 | Jun 1, 2006 | Progen Pharmaceuticals, University of Wisconsin |
| NCT00705874 | Phase 1 | May 1, 2006 | Cancer Centres of the Carolinas, Greenville, SC 29605, Progen Pharmaceuticals |
| NCT00293488 | Phase 1 | Jan 1, 2006 | National Cancer Institute (NCI), Progen Pharmaceuticals |
| NCT00705653 | Phase 1 | Mar 1, 2005 | Progen Pharmaceuticals, University of Chicago |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Progen Pharmaceuticals | For profit | 5 | 4 | 2 | 2005 |
| Cancer Centres of the Carolinas, Greenville, SC 29605 | Academic/Hospital | 1 | 0 | 1 | 2006 |
| Johns Hopkins University | Academic/Hospital | 1 | 0 | 1 | 2007 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2006 |
| University of Chicago | Academic/Hospital | 1 | 0 | 1 | 2005 |
| University of Wisconsin | Academic/Hospital | 1 | 1 | 1 | 2006 |
6 organizations
Page 1 / 1